Opioid Use, Pregnancy
Conditions
Keywords
pregnancy, prescription opioids
Brief summary
To compare maternal and newborn outcomes among pregnant women with OUD receiving care via telemedicine versus in-person.
Detailed description
Participants: Pregnant women with OUD. Intervention: Participants were seen weekly for four weeks, every two weeks for four weeks and monthly thereafter and provided relapse-prevention therapy and buprenorphine. Design: A cohort derived from a prospectively collected database including 98 women receiving perinatal OUD treatment in an obstetric practice by telemedicine or in-person and followed until 6-8 weeks postpartum from September, 2017 to December, 2018. Logistic regression with propensity score adjustment was applied to reduce group selection bias and control for potentially confounding variables. Setting: Four outpatient obstetric practices in the southeast.
Interventions
BEHAVIORALIn-Person Perinatal OUD Treatment
Participants were seen weekly for four weeks, every two weeks for four weeks and monthly thereafter and provided relapse-prevention therapy and buprenorphine as part of standard of care.
BEHAVIORALPerinatal OUD Treatment via Telemedicine
Participants were seen weekly for four weeks, every two weeks for four weeks and monthly thereafter and provided relapse-prevention therapy and buprenorphine as part of standard of care..
Sponsors
Medical University of South Carolina
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to 45 Years
Healthy volunteers
No
Inclusion criteria
* Adult females, any race or ethnicity, age 18-45 years * Currently pregnant * Opioid Use Disorder (OUD) * received in person or telemedicine treatment for OUD in their obstetrician's office
Exclusion criteria
* Not currently pregnant or receiving perinatal care * Not in agreement with Patient-Physician Agreement
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of individuals retained in treatment | 6-8 weeks postpartum | Uninterrupted addiction treatment during pregnancy through 6-8 weeks postpartum |
| Percent of infants born with Neonatal Abstinence Syndrome (NAS) | At Delivery | Newborn withdrawal, also know as NAS gathered via electronic health record |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Positive urine drug screens | At delivery and 6-8 weeks postpartum | Number of individuals with a positive urine drug screen |
| Length of newborn hospital stay and birth weight | Assessed up to 6 months following delivery | Average number of days infant was in the hospital following delivery; weight of infant at birth |
Countries
United States
Outcome results
None listed